Log in

NYSE:USNAUSANA Health Sciences Stock Price, Forecast & News

$84.72
-0.47 (-0.55 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$83.16
Now: $84.72
$85.02
50-Day Range
$66.91
MA: $79.54
$89.22
52-Week Range
$43.01
Now: $84.72
$90.94
Volume156,754 shs
Average Volume252,944 shs
Market Capitalization$1.78 billion
P/E Ratio18.26
Dividend YieldN/A
Beta0.94
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition. It also provides Sensé—beautiful science products, such as personal care products that support healthy skin and hair through topical nourishment, moisturization, and protection; Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
Read More
USANA Health Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.34 out of 5 stars


Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryPersonal Products
SectorMedical
CUSIP90328M10
Phone801-954-7100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.06 billion
Cash Flow$5.75 per share
Book Value$15.11 per share

Profitability

Net Income$100.53 million

Miscellaneous

Employees1,909
Market Cap$1.78 billion
Next Earnings Date7/28/2020 (Estimated)
OptionableOptionable

Receive USNA News and Ratings via Email

Sign-up to receive the latest news and ratings for USNA and its competitors with MarketBeat's FREE daily newsletter.

USANA Health Sciences (NYSE:USNA) Frequently Asked Questions

How has USANA Health Sciences' stock been impacted by COVID-19 (Coronavirus)?

USANA Health Sciences' stock was trading at $69.88 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, USNA stock has increased by 21.2% and is now trading at $84.72. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of USANA Health Sciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for USANA Health Sciences.

When is USANA Health Sciences' next earnings date?

USANA Health Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for USANA Health Sciences.

How were USANA Health Sciences' earnings last quarter?

USANA Health Sciences, Inc. (NYSE:USNA) announced its quarterly earnings data on Tuesday, April, 21st. The company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.66. The company earned $266.62 million during the quarter, compared to analyst estimates of $220.40 million. USANA Health Sciences had a return on equity of 30.09% and a net margin of 9.76%. The firm's revenue was down 2.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.01 earnings per share. View USANA Health Sciences' earnings history.

How will USANA Health Sciences' stock buyback program work?

USANA Health Sciences announced that its board has authorized a stock repurchase program on Wednesday, February 5th 2020, which allows the company to buyback $130,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to buy up to 9.1% of its stock through open market purchases. Stock buyback programs are usually a sign that the company's management believes its shares are undervalued.

What guidance has USANA Health Sciences issued on next quarter's earnings?

USANA Health Sciences updated its FY 2020 After-Hours earnings guidance on Tuesday, April, 21st. The company provided earnings per share (EPS) guidance of 4.00-4.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.01. The company issued revenue guidance of $1-1.08 billion, compared to the consensus revenue estimate of $1.01 billion.

What price target have analysts set for USNA?

4 equities research analysts have issued 1-year price objectives for USANA Health Sciences' stock. Their forecasts range from $65.00 to $75.00. On average, they anticipate USANA Health Sciences' stock price to reach $70.00 in the next year. This suggests that the stock has a possible downside of 17.4%. View analysts' price targets for USANA Health Sciences.

What are Wall Street analysts saying about USANA Health Sciences stock?

Here are some recent quotes from research analysts about USANA Health Sciences stock:
  • 1. According to Zacks Investment Research, "USANA Health Sciences Inc. develops and manufactures high-quality nutritional, personal care and weight management products. The company's three primary product lines consist of nutritional, personal care and weight management products. The company's products are distributed primarily through a network marketing system. " (5/3/2020)
  • 2. Pivotal Research analysts commented, "We thought it noteworthy that the company projected average diluted shares outstanding of 22.7 million, given that 2Q diluted shares out were 23.4 million. To get to that average we expect the company will need to buy-in 1.9 million shares in the 2H. That will put average shares outstanding down 7.7% for the year. This is not so important for 2019, but it will be for next year when we see an earnings recovery of 27% at the net income line (still below 2018) but EPS growth of 38% owing to the reduced share count." (7/24/2019)

Has USANA Health Sciences been receiving favorable news coverage?

Headlines about USNA stock have been trending somewhat negative on Saturday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. USANA Health Sciences earned a daily sentiment score of -1.6 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutUSANA Health Sciences.

Are investors shorting USANA Health Sciences?

USANA Health Sciences saw a decline in short interest in May. As of May 15th, there was short interest totaling 1,570,000 shares, a decline of 16.0% from the April 30th total of 1,870,000 shares. Based on an average daily volume of 268,900 shares, the days-to-cover ratio is currently 5.8 days. Currently, 13.0% of the company's shares are short sold. View USANA Health Sciences' Current Options Chain.

Who are some of USANA Health Sciences' key competitors?

What other stocks do shareholders of USANA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include IBM (IBM), Gilead Sciences (GILD), AT&T (T), Allergan (AGN), AbbVie (ABBV), Amgen (AMGN), Intel (INTC), Intuitive Surgical (ISRG), NVIDIA (NVDA) and Tesla (TSLA).

Who are USANA Health Sciences' key executives?

USANA Health Sciences' management team includes the following people:
  • Dr. Myron W. Wentz, Founder & Chairman (Age 78)
  • Mr. Kevin G. Guest, CEO & Director (Age 56)
  • Mr. Jim Brown, Pres & COO (Age 50)
  • Mr. G. Douglas Hekking, Chief Financial Officer (Age 49)
  • Mr. Walter Noot, Chief Information Officer (Age 53)

What is USANA Health Sciences' stock symbol?

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

Who are USANA Health Sciences' major shareholders?

USANA Health Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.02%), Acadian Asset Management LLC (3.68%), State Street Corp (2.01%), Morgan Stanley (1.05%), Morgan Stanley (1.05%) and Geode Capital Management LLC (1.04%). Company insiders that own USANA Health Sciences stock include Brent Neidig, Daniel A Macuga, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Robert A Sinnott, Robert Auciaux and Walter Noot. View institutional ownership trends for USANA Health Sciences.

Which major investors are selling USANA Health Sciences stock?

USNA stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, AQR Capital Management LLC, BlackRock Inc., JPMorgan Chase & Co., MERIAN GLOBAL INVESTORS UK Ltd, Martingale Asset Management L P, Parametric Portfolio Associates LLC, and Aigen Investment Management LP. Company insiders that have sold USANA Health Sciences company stock in the last year include Brent Neidig, Daniel A Macuga, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Robert Auciaux, and Walter Noot. View insider buying and selling activity for USANA Health Sciences.

Which major investors are buying USANA Health Sciences stock?

USNA stock was acquired by a variety of institutional investors in the last quarter, including Matarin Capital Management LLC, APG Asset Management N.V., APG Asset Management N.V., APG Asset Management N.V., Morgan Stanley, Morgan Stanley, Mackay Shields LLC, and Bogle Investment Management L P DE. Company insiders that have bought USANA Health Sciences stock in the last two years include Global Ltd Gull, and Myron W Wentz. View insider buying and selling activity for USANA Health Sciences.

How do I buy shares of USANA Health Sciences?

Shares of USNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is USANA Health Sciences' stock price today?

One share of USNA stock can currently be purchased for approximately $84.72.

How big of a company is USANA Health Sciences?

USANA Health Sciences has a market capitalization of $1.78 billion and generates $1.06 billion in revenue each year. The company earns $100.53 million in net income (profit) each year or $4.41 on an earnings per share basis. USANA Health Sciences employs 1,909 workers across the globe.

What is USANA Health Sciences' official website?

The official website for USANA Health Sciences is www.usana.com.

How can I contact USANA Health Sciences?

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The company can be reached via phone at 801-954-7100 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.